-+ 0.00%
-+ 0.00%
-+ 0.00%
Lexaria Bioscience Completes Final Dosing On Schedule With Human Pilot Study 7, GLP-1-H26-7, To Evaluate Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy Over Five Weeks
Share
Listen to the news

Final visits were completed this week by all Study participants within all Study arms. With dosing complete and final blood samples taken, the Study work will now shift to laboratory sample analyses, quality control and review of all data, and then reporting.

No information from the Study will be provided to any third parties until all data has been reviewed and quality controlled. Lexaria will provide further information once that has been achieved.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending